Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

Principal Investigator: Dr. Suchitra Krishnan-Sarin

The purpose of this study is to evaluate interactions between a moderate dose of alcohol and a mGLUR5 NAM, when compared with a placebo, on pharmacokinetic, physiological or behavioral responses.

Healthy social drinkers recruited into this project are screened for eligibility during intake and physical exam appointments. These appointments are followed by a baseline lab session where they receive a moderate dose of alcohol, divided into six doses, administered over one and a half hours. Physiological, behavioral and pharmacokinetic parameters are assessed. Participants then take the study medication or placebo for a period of at least 7 days and adverse events are assessed daily. On the last day of medication participants complete a second baseline lab session which is similar to the first one. They also complete a one week follow up.

In 2018-19 we conducted a pilot study testing the safety and efficacy of an investigational medication (an mGluR5 agent) in combination with alcohol.

We are temporarily not enrolling subjects at this time but plan to continue recruitment into our alcohol study in 2020.

Nicholas Franco
34 Park St., CMHC
New Haven, CT 06519
Phone: 203-974-7679
Email: nicholas.franco@yale.edu